title: Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
authors.forename: M
authors.initials: M
authors.lastname: Tiribelli
authors.forename: L
authors.initials: L
authors.lastname: Marin
authors.forename: E
authors.initials: E
authors.lastname: Calistri
authors.forename: A
authors.initials: A
authors.lastname: Geromin
authors.forename: D
authors.initials: D
authors.lastname: Damiani
authors.forename: R
authors.initials: R
authors.lastname: Fanin
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D003131:Combined Modality Therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate